�����ƽ��

In this webinar, Diana Golubeva, Scientist in the Immunology group at �����ƽ�� Technologies, presents a robust, scalable platform for differentiating human pluripotent stem cells (hPSCs) into functional immune cells for allogeneic cell therapy development. By integrating TeSR™-AOF 3D for xeno-free suspension culture and STEMdiff™ Hematopoietic-EB reagents, the protocol enables efficient, high-yield generation of CD34⁺ hematopoietic stem and progenitor cells (HSPCs). These HSPCs serve as a foundation for downstream differentiation into lymphoid lineages—including natural killer (NK), T, and B cells—using STEMdiff™ and StemSpan™ kits, all optimized for feeder-free workflows and scalable bioreactor formats.<br><br>As a supporter of, and participant in, ISSCR’s 2025 Annual Meeting, we share with you our presentation at ISSCR 2025. This presentation does not represent an endorsement from or support of the ISSCR.

Join �����ƽ�� scientists Tia Sojonky and Sarah McManus to learn all about hPSC scale-up and differentiation in 3D suspension culture. This webinar provides an in-depth look at advanced techniques for scaling up and differentiating hPSCs, with some practical tips for getting started and a 15-minute Q&A session that addresses some of the most pressing questions from the field.

Obtaining consistent and reliable results when culturing immune cells can be challenging. Watch this webinar to discover how to obtain high yields of functional T cells, NK cells, B cells, dendritic cells, and macrophages for your research applications. The speaker, Evan Karas, also explains how to expand primary T cells without feeders or serum.

Hear from Dr. Maxime Feyeux, who discusses what the in vivo growth environment of pluripotent stem cells (PSCs) can teach us about in vitro culture. He summarizes some of the current challenges facing standard PSC culture technologies and shares a solution for mass producing high-quality PSCs for downstream applications.

Each year, more human pluripotent stem cell-derived (hPSC-derived) therapies move towards the clinic, and �����ƽ�� is committed to supporting researchers from discovery to clinical application. In this Innovation Showcase from ISSCR 2021, Lynn Csontos will demonstrate how we build quality into our products, processes, and policies to support your project timing, product quality, and overall vision. Kimberly Snyder will then present data that shows how TeSR™-AOF, a novel animal origin-free (AOF) hPSC maintenance medium, can support optimized cell quality, improved performance and reproducibility across all cell lines.

Overview of the derivation of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs)

Technical tip from our dedicated team of Product and Scientific Support specialists